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Abstract: Microbicides are compounds that applied vaginally or rectally, protect the user from 
sexually transmitted infections. Although no commercial product is yet available, many candi-
dates are under development. A leading candidate, VivaGel™ (SPL7013 Gel) is the product of 
nanotechnology. The active ingredient is SPL7013, a dendrimer that was designed speciﬁ  cally 
with HIV and HSV antiviral activity and human safety in mind. SPL7013 has demonstrated 
efﬁ  cacy against human immunodeﬁ  ciency virus and herpes simplex virus in in vitro and animal 
models. VivaGel™ appears to be well tolerated in both animals and humans. This review sum-
marizes the studies of VivaGel™ and its active ingredient, SPL7013.
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Introduction
In 2005, an estimated 4.1 million people worldwide were newly infected with human 
immunodeﬁ  ciency virus (HIV) (UNAIDS 2006). The mainstay for controlling the 
AIDS epidemic remains prevention. Unfortunately, the development of a vaccine 
has proven elusive; therefore prevention has relied primarily on behavioral changes 
including condom use. Many males are unwilling to use condoms thus placing their sex 
partner(s) at risk. Microbicides are compounds that when applied vaginally or rectally 
would protect the user from sexually transmitted infections (STIs). Microbicides could 
offer additional protection when combined with condoms or be used alone as a means 
of protection for women unable to negotiate condom use. Although the emphasis has 
been on preventing HIV, protection from other STIs is desirable in terms of avoiding 
illness and associated sequelae. Importantly, many STIs may increase vulnerability to 
HIV infection (eg, genital herpes infection facilitates the transmission of HIV).
Microbicides, like vaccines, will be used by healthy individuals to protect against 
infections. Like vaccines, microbicides will need to be both highly efﬁ  cacious and 
display an excellent safety proﬁ  le. These products should have little or no effect on 
host defenses including the normal vaginal or rectal microﬂ  ora, the mechanical barrier 
provided by intact epithelium and a variety of innate and adaptive immune responses 
(Turpin 2002). Studies using in vitro systems and animal models are important tools 
in the preclinical development of microbicides.
Dendrimers are a relatively new class of compounds that hold the potential to be 
safe and effective microbicides (McCarthy 2005). Many biologic targets are large 
complex macromolecules (eg, membrane receptors) on the scale of 1–100 nm. These 
macromolecules rely on polyvalent interactions for binding and initiating biologic 
processes. To date, most pharmaceutical development has focused on low molecu-
lar weight drugs that lack the capacity to interact with such targets in a multivalent 
manner. Dendrimers are “nanoscale” macromolecules that can be built with various International Journal of Nanomedicine 2007:2(4) 562
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properties including the ability to interact polyvalently with 
a target. Dendrimer production is a highly controlled staged 
process that allows for the synthesis of precisely deﬁ  ned 
macromolecular structures. The result is a highly branched 
three-dimensional molecule that may possess various surface 
features. SPL7013 is a dendrimer that was developed by 
Starpharma (Melbourne, Victoria, Australia) and contains 
a speciﬁ  cally designed polyanionic surface. This highly 
charged surface allows SPL7013 to attach to targets on 
viruses, blocking viral attachment and/or adsorption to cells 
thereby preventing infection. In the case of HIV, SPL7013 
is thought to bind gp120 proteins on the surface of the virus, 
through which the virus normally attaches to CD4 receptors 
on human cells.
SPL7013 is the active product in the candidate microbi-
cide, VivaGel™ (SPL7013 Gel). Recognizing its potential, the 
United States Food and Drug Administration (FDA) granted 
VivaGel™ Fast Track status in January 2006 for the preven-
tion of HIV indication (Starpharma 2006a). The Fast Track 
program facilitates and expedites development of products 
that serve unmet medical needs of serious or life-threatening 
conditions. Recently, in collaboration with Starpharma, the 
United States National Institutes of Health (NIH) submitted a 
second Investigational New Drug application (IND) to FDA 
for the prevention of HSV-2 indication. This paper reviews 
the data on the safety and efﬁ  cacy of VivaGel™.
VivaGel™ chemistry
VivaGel™ is a water-based vaginal product of 3% weight/
weight (w/w) SPL7013 mixed in Carbopol® gel buffered to 
a pH physiologically compatible with the normal human 
vagina.
SPL7013 is built from a divalent core, the benzhydryl-
amine amide of L-lysine (McCarthy 2005). To this core, 
four successive layers of the branching units, L-lysine 
are added creating a dendrimer with 32 amine groups on 
the surface. A sodium 1-(carboxymethoxy) naphthalene-
3,6-disulfonate group is attached to each of the 32 amine 
surface groups via amide linkers. The chemical product 
is BHA.lys15lys16(NHCOCH2O)1-(3,6-naphth(SO3Na)32 
(BHA = benzhydrylamine) with a molecular weight of 
16,581 daltons. High performance liquid chromatography 
(HPLC) and liquid chromatography/mass spectrometry are 
employed in manufacturing to ensure a single molecular 
entity is synthesized. Purity is determined by HPLC, capillary 
electrophoresis, and electrospray mass spectral analysis.
Carbopol® gel was chosen because of its mucoad-
hesive properties and its use in other vaginal products 
and microbicide formulations. Carbopol® 971P NF is a 
cross-linked acrylic acid listed in the USP Monograph as 
Carbomer 941 and is categorized by the FDA as a generally 
regarded as safe (GRAS) excipient. It is a weak acid with 
high buffering capacity and has been shown to be partially 
effective at inhibiting herpes simplex virus in mice and 
partially effective against HIV-1 in vitro.
The results of in vitro and in vivo studies of SPL7013 
and the formulated product Vivagel™ are discussed in the text 
below. Summaries of the safety and efﬁ  cacy are included in 
Tables 1 and 2.
In vitro studies
Gong et al (2005) evaluated SPL7013 for efﬁ  cacy against 
herpes simplex virus (HSV) and for cell cytotoxicity. Efﬁ  -
cacy against infection was tested by incubating Vero cells 
(African green monkey kidney cells) with SPL7013 prior to 
the addition of the viral inoculum (pre-infection prophylaxis). 
Plaque reduction assays demonstrated the 50% effective 
concentration (EC50) against infection as 2.0 μg/ml for HSV 
type-1 (HSV-1) and 0.5 μg/ml for HSV type-2 (HSV-2). 
Viral absorption to the Vero cells was completely inhibited 
at SPL7013 concentrations 3 μg/ml.
Antiviral activity in cells already infected with HSV-1 or 
HSV-2 was demonstrated as well (post-infection treatment). 
EC50 for treating infections were 6.1 μg/ml for HSV-1 and 
3.8 μg/ml for HSV-2. Time-of-addition studies indicated 
that SPL7013 inhibited both cell entry and HSV replica-
tion suggesting that it may have potential as a therapeutic 
agent for HSV infections. SPL7013 was shown to provide 
comparable protection and antiviral activity against a HSV-2 
strain resistant to penciclovir/acyclovir and a HSV-1 strain 
resistant to foscarnet.
SPL7013 was not toxic to Vero cells up to the highest con-
centration tested, 10,000 μg/ml. Effects on cell proliferation 
were tested on two epithelial cell lines (Hela-229 and Hep-2) 
in both stationary and dividing phases. The 50% cytotoxic 
concentrations (CC50) on both cell lines were greater than the 
highest concentration tested (10,000 μg/ml).
By serial passage in the presence of increasing con-
centrations of SPL7013, Gong et al (2005) generated an 
HSV-1 strain that was resistant to post-infection dendrimer 
treatment but not pre-infection dendrimer prophylaxis. 
Using this approach the investigators were unable to create 
a dendrimer-resistant HSV-2 strain. This suggested it was 
possible to develop resistance to the effects of SPL7013 on 
viral replication but not on the mechanism(s) responsible for 
preventing infection.International Journal of Nanomedicine 2007:2(4) 563
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Dezzutti et al (2004) evaluated the cytotoxicity and 
anti-HIV activity of serial dilutions of 5% w/w SPL7013 in 
the VivaGel™ formulation. Cellular toxicity was appraised in 
peripheral blood mononuclear cells (PMBCs), macrophages 
(mΦ), urogenital and colorectal cell lines. SPL7013 was 
found to be relatively nontoxic and its toxicity was similar 
to that of the base Carbopol® gel. The ability of mucosal 
epithelial cells to maintain an intact, polarized monolayer 
in the presence of the various candidates was evaluated by 
measuring transepithelial resistance (TER). TER was affected 
very little by SPL7013. Anti-HIV activity was evaluated in 
assays for prevention of infection of PMBCs and mΦ as 
well as for prevention of the transfer of infectious HIV-1 
from epithelial cells to activated PMBCs. SPL7013 blocked 
infection of mΦ by 2 log10 (99% inhibition).
The safety and efficacy of SPL7013 for rectal use 
was evaluated using colorectal explants obtained from 
patients undergoing bowel surgical resection for non-
inﬂ  ammatory disease. (Abner et al 2005). Explants exposed 
to 5% SPL7013 underwent epithelial sloughing leaving the 
lamina propria intact whereas the control explants treated 
with the nonoxynol-9 suffered sloughing and necrosis of 
the lamina propria. As is described below, any epithelial 
sloughing attributed to SPL7013 in these explant studies 
is in contrast to the safety proﬁ  le of VivaGel™ following 
repeated rectal administration in nonhuman primate studies. 
A decrease in explant viability was detected after application 
of both SPL7013 and the placebo Carbopol® gel by a MTT 
(1-(4,5-dimethylthiazol-2yl)-3,5-diphenylformazan) assay. 
Anti-HIV efﬁ  cacy was evaluated utilizing HIV-1 CXCR4-
using (R4) and CCR5-using (R5) strains. Transmission 
of HIV-1 infection to the rectal epithelium was reduced 
by 85% with SPL7013 and by 50% with the base 
Carbopol® formulation alone.
Nonprimate animal studies
Bernstein et al (2003) evaluated SPL7013 in vitro and 
in animal models. The in vitro studies utilized Vero 
cell cultures incubated with different concentrations of 
unformulated SPL7013 to evaluate cell cytotoxicity and 
effectiveness against HSV-2 infection. The group found 
an EC50 of 0.6 μg/ml while the CC50 was greater than the 
maximum 1000 μg/ml tested.
The effect of SPL7013 drug concentration and duration 
of protection was evaluated. Mice were treated vaginally 
with 100 mg/ml, 10 mg/ml, 1 mg/ml SPL7013 or phosphate 
Table 1 Brief summary of safety studies
In vitro studies
Gong et al (2005)
SPL7013 found nontoxic to Vero cells in highest concentration tested (10,000 μg/ml)
Dezzutti et al (2004)
SPL7013 was relatively nontoxic to peripheral blood mononuclear cells, macrophages, urogenital and colorectal cell lines. Its toxicity was similar to 
that of the base carbopol gel. SPL7013 had very little effect on the ability of mucosal epithelia cells to maintain an intact, polarized monolayer when 
measured by transepithelial resistance.
Abner et al (2005)
The 5% formulation in colorectal explants caused epithelial sloughing while the lamina propria remained intact whereas nonoxynol-9 caused sloughing 
and necrosis of the lamina propria.
Bernstein et al (2003)
In Vero cells, the cytotoxic concentrations (CC50) was higher than the maximum concentration tested (1000 μg/ml).
In vivo studies
Bernstein et al (2003)
In a 5-day repeat dose rabbit vagina model, the 5, 1 and 0% formulations all elicited the same minimal level of vaginal irritation.
Patton et al (2006)
In a 4-day repeat dose macaques vagina model, the 5% but not the 3% or 1% formulation caused irritation visible by colposcopic examination. The 
3% did not cause histologic changes on biopsy. Rectal application of the 3% formulation yielded rectal lavage specimens no different than those of 
untreated animals.
Jaing et al (2005)
In vitro studies yielded a cytotoxic dose (CD50) of 1500 μM for macaques peripheral blood mononuclear cells and 2250 μM in two different human 
cell lines. Clinical observation did not ﬁ  nd any signs of macaques vaginal irritation with a single dose of the 1%, 3% and 5% formulations.
Human study
McCarthy et al (2005)
A phase I human clinical trial demonstrated that 0.5%–3.0% SPL7013 formulations were safe and well tolerated following once daily vaginal application 
for 7 days. In addition, the SPL7013 was not absorbed systemically.International Journal of Nanomedicine 2007:2(4) 564
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buffered saline (PBS) and challenged 20 seconds later with 
HSV-2. A dose related response was noted with 12/12, 
10/12, 6/12 and 0/12 mice being protected from infection, 
respectively. The 10 mg/ml concentration was tested with 
HSV-2 challenges at 5, 30, or 60 minutes following SPL7013 
prophylaxis. Protection against infection was seen at each 
respective time in 14/16, 12/16 and 4/15 mice. All PBS 
treated controls became infected.
Vaginal gel prototypes were prepared with various 
concentrations of SPL7013 in three different Carbopol® 
formulations differing in the amount of propylene glycol 
and glycerin. Gels containing 5, 1 and 0% w/w SPL7013 
were evaluated in a 5-day repeat dose rabbit vaginal irrita-
tion model and all elicited the minimal vaginal irritation. The 
5, 1 and 0% w/w SPL7013 concentrations in the different 
Carbopol® formulations were tested in mice against a 
HSV-2 challenge at 5 and 30 minutes following prophy-
laxis. All three formulations with either the 5 or 1% w/w 
SPL7013 provided signiﬁ  cant protection at both time points 
(63%–100% efﬁ  cacy).
Based on these animal studies the Carbopol® formula-
tion containing 1% w/w glycerin and propylene glycol was 
selected for further vaginal testing in the guinea pig model 
of genital herpes disease and is now referred to as VivaGel™. 
The guinea pig model is felt to closer approximate human 
genital herpes disease than the mouse model. Concentrations 
of 1%–5% w/w SPL7013 were evaluated with a HSV-2 
challenge at 5 minutes following prophylaxis. The results 
showed high levels of protection were provided by 3% and 
5% w/w SPL7013 formulations. This same Carbopol® for-
mulation was selected for evaluation in subsequent primate 
model studies.
In June 2006, Starpharma (2006b) announced that 
preliminary studies suggest that SPL7013 exhibits con-
traceptive activity in a rabbit model. The mechanism of 
contraceptive action is postulated to be interference with 
attachment/fertilization. The study, performed at Johns 
Hopkins University (Baltimore, Maryland, USA), used two 
formulations of 3% SPL7013. A 75% reduction in embryos 
was seen with the SPL7013 Carbopol® gel formulation and 
a 95% reduction with the SPL7013 HEC (hydroxyethyl 
cellulose) gel formulation. The reduction in the number of 
embryos in rabbits was similar to that produced by contra-
ceptive products containing nonoxynol-9.
Nonhuman primate safety
and efﬁ  cacy studies
Investigators at the University of Washington at Seattle 
(Patton et al 2006) studied the safety and efficacy of 
SPL7013 vaginal gels in pigtailed macaques. In a com-
parative study, three concentrations (1%, 3% and 5% w/w 
SPL7013) and the base Carbopol® gel alone (placebo) were 
administered intravaginally once daily for four consecutive 
days. Cervicovaginal irritation was seen on colposcopy in 
Table 2 Brief summary of efﬁ  cacy studies
In vitro
Gong et al (2005)
SPL7013 was effective protecting Vero cells from HSV infection with an effective concentration (EC50) of 2.0 μg/ml for HSV-1 and 0.5 μg/ml for HSV-2. 
Inhibitory effects were observed in HSV infected cells indicating a therapeutic potential for SPL7013
Dezzutti et al (2004)
The 5% SPL7013 formulation inhibited by 99% HIV infection of human macrophages in vitro
Abner et al (2005)
Transmission of HIV-1 (R4/R5 strains) infection to the rectal epithelium in explants was reduced by 85% with the 5% SPL7013 formulation
Bernstein et al (2003)
Unformulated SPL7013 protected Vero cells from HSV-2 infection
Jaing et al (2005)
In vitro SPL7013 inhibits infections by HIV and SHIV in human cell lines and macaque PBMCs
In vitro
Bernstein et al (2003)
Formulated product improves duration of protection for at least one hour in the mouse vaginal model. Guinea Pig vaginal model suggested formula-
tion should be 3%–5% SPL7013 for optimal protection
Patton et al (2006)
The 3% formulation was not effective against cervical challenge with Chlamydia trachomatis in macaques
Jaing et al (2005)
Formulations of 3% and 5% SPL7013 effectively blocked vaginal transmission of SHIV in macaquesInternational Journal of Nanomedicine 2007:2(4) 565
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four of the six animals administered the 5% w/w SPL7013 
formulation but in none of the animals receiving the 3% w/w, 
1% w/w SPL7013 or placebo gel. Vaginal and cervical 
biopsies collected 24 hours after the fourth application of 
the 3% gel and placebo appeared similar to those obtained 
at baseline. A transient impact on vaginal microﬂ  ora was 
seen 30 minutes after application in all groups but no pat-
tern of a sustained shift in organisms was noted. Vaginal pH 
was signiﬁ  cantly lower 30 minutes after application of the 
SPL7013 formulations but had returned to baseline by the 
fourth day after the ﬁ  nal application. The pH change is due 
to the difference between the pH of the formulations (pH 5) 
and the higher pH of the normal macaque vagina. VivaGel™ 
has been formulated at pH 5 to be physiologically compatible 
with the normal acidic nature of the human vagina.
Based on the results of the vaginal tests, the 3% w/w 
SPL7013 formulation was selected for study in the rectal 
model. The macaques received either the 3% w/w SPL7013 
formulation or the base Carbopol® gel alone (placebo) intrar-
ectally on three consecutive days or received no treatment at 
all. The safety of VivaGel™ in this model was demonstrated 
following collection of rectal lavages and their evaluation for 
evidence of epithelial damage (ie, cellular debris, epithelial 
sheets and blood and/or stroma associated with the epithe-
lial sheets). This analysis showed there were no signiﬁ  cant 
differences between the animals in the nontreated control 
group and those animals treated with the 3% w/w SPL7013 
and placebo gels. There were no signiﬁ  cant differences in 
microﬂ  ora between all the groups. Rectal pH was signiﬁ  -
cantly lower in the placebo and 3% w/w SPL7013 gel groups, 
which reﬂ  ects the pHs of these formulations relative to the 
pH of the macaque rectum, and recovered by 24 hours after 
the last application.
The efﬁ  cacy of the 3% w/w SPL7013 gel for the pre-
vention of cervical Chlamydia trachomatis infection was 
assessed. Four of the six animals that received the 3% w/w 
SPL7013 gel and ﬁ  ve of the six animals that received no 
product developed infection following intravaginal inocula-
tion. SPL7013 did not prevent cervical chlamydial infection 
in this model.
Jaing et al (2005) demonstrated anti-retroviral activity in 
vitro against both CXCR4-using (R4) and CCR5-using (R5) 
HIV and SHIV (chimeric simian-human immunodeﬁ  ciency-1 
virus) strains in human and simian cell lines. In addition, 
SPL7013 showed very low cytotoxicity in cell culture. 
Based on these ﬁ  ndings for unformulated SPL7013, the 
ability of a single intravaginal application of VivaGel™ to 
block vaginal SHIV transmission was tested. Following 
challenge, all untreated pigtailed macaques (8/8) and seven 
of the eight animals given the base Carbopol® formulation 
without SPL7013 (placebo gel) developed SHIV infection as 
indicated by plasma viremia and CD4+ cell decline. A dose-
dependent response was observed among the SPL7013 
treated macaques; 6/6, 5/6, and 2/6 animals treated with 
the 5%, 3% and 1% w/w SPL7013 gels, respectively, were 
protected against infection. The uninfected animals were 
followed for over a year and remained SHIV negative by 
serology and lymph node biopsy. Clinical observation did 
not reveal any signs of toxicity or vaginal irritation due to 
the single application of the SPL7013 formulations.
Human trials
A phase I clinical trial involving 36 healthy women was 
completed in 2004 (McCarthy 2005). VivaGel™ preparations 
containing 0.5%–3.0% w/w SPL7013 were evaluated for 
safety in comparison to the base Carbopol® formulation 
without SPL7013 (placebo gel). Women received either 
VivaGel™ or placebo once daily intravaginally for 7 days. All 
SPL7013 concentrations of VivaGel™ were found to be safe 
and as well tolerated as placebo. SPL7013 was not absorbed 
into the systemic circulation simplifying the toxicological 
aspects about this drug.
Summary
SPL7013 is a dendrimer developed speciﬁ  cally to work 
as a microbicide against HIV and HSV-2. In vitro and 
animal model studies have demonstrated the efﬁ  cacy of 
the unformulated dendrimer in protecting against both 
HSV and HIV infections. VivaGel™, at SPL7013 concen-
trations up to and including 3% w/w, was shown to be 
safe following vaginal or rectal application in macaques 
and protected macaques against vaginal SHIV infection. 
A Phase I clinical trial in humans demonstrated VivaGel™ 
was well tolerated. Further trials are planned to expand on 
the initial Phase I clinical trial and to evaluate VivaGel™ 
for the prevention of HIV and HSV-2 genital infections in 
women. (Starpharma 2006c).
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